U.S. Markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
281.77-2.65 (-0.93%)
At close: 4:00PM EDT
People also watch
CELGREGNGILDAMGNALXN
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • d
    dornweg
    dornweg
    if you bought the upgrade a day or two ago, you got snookered."'.Reuters reports that Democrats on the House Committee on Oversight and Government Reform have launched an investigation into price increases for multiple sclerosis (MS) drugs. Seven firms have received letters requesting information'....'".Of the seven firms contacted, Biogen has the largest exposure to the MS arena, accounting for more than 88% of its Q2 product sales"
  • H
    Haliako
    Haliako
    $300 stock!!!
  • G
    Gargoyle
    Gargoyle
    “The system is broken.”
    Drug Puts A $750,000 ‘Price Tag On Life’
    The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
    khn.org
  • w
    whooz yor daddy
    whooz yor daddy
    This was on Fidelity: ...11:38 ET - Biogen (BIIB) down 1%, as the stock reverses from pre-market gain of 2.9%. Shares jumped before the open based on big sales beat for Spinraza, company's new rare disease drug whose 2Q sales were nearly three times greater than analysts forecast. Jefferies says the decline during regular session driven by a mix of profit taking, lack of long term guidance from management, and other factors. Also hurting the stock is that company didn't announce any new share repurchases, and signaled there may not be any coming in near-term. BIIB will shift capital allocation away "from emphasizing share repurchases to prioritizing business development and investing for growth," CEO Michel Vounatsos says on conference call.
  • S
    Saltynacho
    Saltynacho
    whooz yor daddy - Are you going to stop whining now???
  • .
    .
    .
    Looks like Chevy was right, this stock is garbage. IBB and FBIOX are both near 52 week highs and that is WITHOUT AMGN, BIIB and other top holdings. All the recent bio sector gains are from the new kids. Between AMGNs earnings and the useless Italy news, what's this junk going to be at tomorrow like -70?
  • A
    Anonymous
    Anonymous
    explain to me how the stock is down after that earnings report? I just don't get it.
  • .
    .
    .
    AMAZING... Got a GS upgrade to $338 and we're already starting to sell off pre-market.
  • p
    paul
    paul
    Cheers to all longs!!
  • Z
    Zo
    Zo
    biib >> LNTH
  • H
    Hoon
    Hoon
    guys help i bought in premarket and im new with this...what should i do
  • A
    Anonymous
    Anonymous
    This stock refuses to go higher even after good quarter and upgrades. It is DEAD money to me now!!! so frustrating
  • Z
    Zef
    Zef
    Headed to 240 just like the last earnings cycle
  • w
    whooz yor daddy
    whooz yor daddy
    Last ER Clancy sold a bunch of shares as he was exiting (4/25) stock sold off from its 291 high with vengeance. I am hopeful we won't have to worry about this scenario this time around Sure would like to see this north of $300 again. Long time since we've seen this.
  • .
    .
    .
    What happened to all the acquisitions BIIB promised? All it did was buy one little drug. Same with GILD. They promised acquisitions too.
  • A
    Andrea
    Andrea
    How is this Down ? Great report and raised guidance. PE is 16.5 with forward PE of 14. I have held since the 120's and will continue to hold. Regret not selling some in the 400's though
  • H
    HotPicks
    HotPicks

    KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • .
    .
    .
    Has nothing to do with Bios people... only down ahead of the healthcare vote. Entire bios and healthcare sector is down.
  • w
    whooz yor daddy
    whooz yor daddy
    I'm done.. It did the same flippin thing last time when reporting. Huge run then sells off. Something is vastly wrong here!